FDA Approves Regeneron’s Pasatru for Fibrodysplasia Ossificans Progressiva, Expanding Treatment Options

As reported on BioSpace, the U.S. Food and Drug Administration has approved Regeneron’s Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that causes bone to…

Continue Reading FDA Approves Regeneron’s Pasatru for Fibrodysplasia Ossificans Progressiva, Expanding Treatment Options

Breaking New Ground: FDA Approves First Gene Therapy to Address the Root Cause of GSDIa

Historic Milestone Offers Relief from Relentless Burden of Glycogen Storage Disease Type Ia According to a recent press release from Ultragenyx, after decades of medical innovation and tireless advocacy from…

Continue Reading Breaking New Ground: FDA Approves First Gene Therapy to Address the Root Cause of GSDIa

TransThera Secures China’s First Approval for Patients With FGFR Inhibitor-Resistant Cholangiocarcinoma

As reported by allsci, China’s National Medical Products Administration (NMPA) has granted conditional approval to TransThera Sciences’ Yochanra (tinengotinib) for adults with unresectable, advanced, or metastatic cholangiocarcinoma (CCA) carrying FGFR2…

Continue Reading TransThera Secures China’s First Approval for Patients With FGFR Inhibitor-Resistant Cholangiocarcinoma